Since 1986 MetaSystems has been designing and manufacturing systems for computerized automated microscopic imaging. From the very beginning, the close relationship to the end user has been an essential part of the MetaSystems philosophy. The following three decades have revealed that this was a successful strategy; from humble beginnings, MetaSystems has grown into a leading solution provider which still remains connected to its strong roots.
MetaSystems’ latest innovation, Neon, is a dynamic, modern imaging platform which reliably manages cases, images, and results from single workstation environments to large multi-user, multi-site installations. The Neon imaging platform ensures that all relevant information is accessible whenever needed.
Maybe you can find a solution to your imaging automation problem here on this web site. We recommend starting your journey on the application pages, if you are not familiar with our product portfolio. In case you are, it may be easier to go directly to the page for the product you actually look for. Should you feel lost, please feel free to contact us or the MetaSystems partner in your country.
We believe in communication being the first step towards innovative solutions!
Your cookie settings prevent this video from being displayed.
Circulating tumor cells (CTCs) are cancer cells shed from primary or metastatic solid tumors into peripheral blood, whereas circulating endothelial cells (CECs) are derived from endothelial cells (ECs) of blood vessels into circulation. Clinical relevance of CTCs in tumor metastasis and prognosis [...], CECs in tumor angiogenesis [...], and CEC clusters in carcinoma [...] have been substantially discussed elsewhere. [...] Detection of circulating rare cells (CRCs), including both CTCs and CECs, is the most representative of liquid biopsy due to its unique availability of frequent and non-invasive detecting tumor cells in carcinoma patients. [...] Somatic aneuploidy is the most common characteristic of human carcinomas [...]. Approximately 90% of solid tumors and 75% of hematological carcinomas exhibit aneuploidy [...]. In particular, aneuploid chromosome 8 (Chr 8) was observed in neoplasm cells of several solid tumors, including lung, gastric, pancreatic, colon, bladder, esophageal, and hepatocellular carcinomas, etc. [...]. [...] The established SE-iFISH strategy, facilitated by the newly developed Metafer-iFISH [...] automated CRC image scanning and analysis system [...], provides a unique comprehensive platform to effectively detect, phenotypically and karyotypically characterize CRCs with cytogenetic abnormalities of chromosome aneuploidy or gene rearrangements (such as ALK gene) in situ, in both patients and PDX tumor animal models.
Cited From: Diagnostics (Basel, Switzerland) (2018)
Read more...
All Publications
MetaSystems Probes now has its own website. If you are looking for MetaSystems XCyting DNA Probes, please visit the MetaSystems Probes website.
The 33th "Tumorgenetische Arbeitstagung 2021", organized by the German Society for Human Genetics (GfH). One of the central tasks of the GfH is to promote human genetics in all areas of research, teaching and practice.
Researchers led by University of Milan dermatologist Raffaele Gianotti and pathologist Prof. Massimo Barberis, director of the Molecular Pathology Unit at Institute of European Oncology in Milan report evidence of early SARS-CoV-2 infection in an Italian patient published in the British Journal of Dermatology. The detection was achieved using the XRNA SARS-CoV-2 FISH probe and Metafer as the analysis system.
The image is a screenshot of the respective report broadcasted by Italian News Channel RAI.
Wibu-Systems has disclosed several vulnerabilities in their software CodeMeter Runtime. This software is also used by our products for license management. Wibu-Systems has released an updated version of the CodeMeter Runtime which addresses these issues. We strongly advise you to install the new version 7.10b or higher.
Please select your country of residence. Choose International if your country is not listed.
Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, it is required that you select the site which is appropriate for your country of residence.
